3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
5
CNS
5
NET
4
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Sarcoma, Synovial
1
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Radiotherapy
3
Doxorubicin
3
Ifosfamide
2
Filgrastim
2
tipifarnib
1
olaparib
1
lutetium Lu 177 dotatate
1
guadecitabine
1
Tamoxifen
1
Specimen Handling
1
Ritonavir
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Ipilimumab
1
Indinavir
1
Immunotherapy
1
Genetic Testing
1
Fluorodeoxyglucose F18
1
Floxuridine
1
Drug Therapy
1
Cisplatin
1
Chemotherapy, Adjuvant
1
CTLA-4 Antigen
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
lutetium Lu 177 dotatate
×
Sarcoma
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled